Parenteral short-term corticosteroid therapy in moderate to severe dermatoses. A comparative multiclinic study.
Six separate investigators following the methodology stipulated in a common protocol provided a data base of 124 patients with Rhus dermatitis, other contact dermatitis, or atopic dermatitis. In this double-blind study, one or two 1 ml (4.0 mg/ml) intramuscular injections of the new sodium phosphate ester of betamethasone was compared with dexamethasone sodium phosphate in the treatment of the signs and symptoms common to these disorders. The comparably balanced groups responded dramatically to both drugs. Within 24 hours the mean scores of all symptoms and patients' overall condition were reduced appreciable. Pruritus, burning, inflammation and other typical symptoms and signs each responded well. The significant beneficial differences were observed most often in patients on betamethasone. There were no treatment failures and no side effects in this short-term trial.
D000293:Adolescent; D000328:Adult; D001623:Betamethasone / Q000008:administration & dosage* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D003877:Dermatitis, Contact / Q000188:drug therapy*; D011040:Dermatitis, Toxicodendron / Q000188:drug therapy*; D003907:Dexamethasone / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged
D003907:Dexamethasone; D001623:Betamethasone